01873.HK
Viva Biotech Holdings
HKSE · Healthcare · Biotechnology · CN
HKD 1.34
−2.20%Aug 26, 2026, 10:23 UTC
Viva Biotech Holdings announced its interim results for the six months ended June 2026, with revenue of RMB 1.007 billion, up 21% year-on-year, and net profit of RMB 80.08 million, down 34.3%.
Source:Aug 20, 2026, 01:46 UTC
On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.
Source: